New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 22, 2014
07:06 EDTISISIsis Pharmaceuticals' ISIS-FXI shows positive Phase 2 data
Isis Pharmaceuticals announced positive top-line data from a Phase 2 comparator-controlled study evaluating the incidence of venous thrombolic events in patients treated with ISIS-FXIRx undergoing total knee replacement surgery, or total knee arthroplasty. ISIS-FXIRx inhibits the production of Factor XI, a coagulation factor that plays a key role in thrombosis. Patients treated with 300 mg of ISIS-FXIRx experienced a seven-fold lower incidence of VTEs compared to patients treated with enoxaparin. Patients treated with 200 mg of ISIS-FXIRx had comparable incidence of VTEs compared to patients treated with enoxaparin. .
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 23, 2015
18:04 EDTISISIsis Pharma granted FDA orphan status for treatment of familial chylomicronemia
Subscribe for More Information
08:58 EDTISISIsis Pharmaceuticals shares not reflecting SMA data, says Needham
Subscribe for More Information
June 22, 2015
07:01 EDTISISIsis Pharmaceuticals reports data from ISIS-SMN Rx in Phase 2 study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use